Aecom vs Summit Therapeutics Inc — how do they compare? Aecom trades at $61.32 (market cap $8.62B), while Summit Therapeutics Inc trades at $15.01 (market cap $12.06B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Aecom pays a 1.77% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ACM | SMMT | |
|---|---|---|
Market Cap | $8.62B | $12.06B |
Sector | Industrials | Health |
52-Week High | $134.35 | $26.98 |
52-Week Low | $66.86 | $12.55 |
Enterprise Value | $10.81B | $11.39B |
Dividend Yield | 1.77% | — |
Signals from Pluang's Aura AI — not financial advice
ACM's stock declined 15.32% to $62.07, driven by a Q2 2026 earnings miss with a loss of $0.50 per share versus a $1.46 estimate, alongside a securities fraud investigation announcement (Business Wire, August 11, 2026). Technical indicators are bearish, with support at $62. Despite this, revenue reached $16.14 billion in 2025, and analyst consensus remains positive with a $88.25 price target and 64% buy ratings.
The outlook is mixed: strong fundamentals like a low P/S of 0.57 and record backlog offer upside, but near-term risks from project delays and legal scrutiny may pressure the stock. Earnings volatility and negative ROE/ROA highlight execution challenges, requiring careful monitoring of quarterly results and legal developments for investor confidence.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Trailing returns across standard periods
Latest headlines on both assets
Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.
Read more on ACM →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →